Arrowhead Pharmaceuticals announced that its drug REDEMPLO (plozasiran) is now prescribable and reimbursable in Germany for Familial Chylomicronaemia Syndrome (FCS), following its EU marketing authorization. This development opens a significant European market for the company's rare disease treatment, potentially boosting revenue and market share.
Arrowhead Pharmaceuticals has achieved a significant milestone with REDEMPLO's authorization and reimbursement in Germany, a major European market. This allows the drug to be prescribed and sold, providing a new revenue stream for the company. The authorization is based on strong Phase 3 trial results, indicating a high efficacy for a rare disease with unmet needs. This development is a positive catalyst for ARWR, as it translates regulatory approval into commercial opportunity, potentially leading to increased sales and market penetration in the short to medium term. The broader diagnostic criteria (clinical symptoms or genetic test) could also expand the eligible patient population.